VA Awards New Contract for Useless Drug
Saturday, August 27, 2011
On August 2 researchers with the Department of Veterans Affairs published a paper that concluded the anti-psychotic drug, risperidone, was no more effective than a placebo when it came to helping veterans suffering from post-traumatic stress disorder.
Despite the availability of this information, the VA on August 11 ordered 20 million more risperidone pills from Mylan Pharmaceuticals.
The value of the Mylan contract was not made available. But it is known that the VA had spent more than $700 million on the drug before the new purchase was made.
Risperidone is the generic name for Risperdal, first developed by the Janssen Pharmaceuticals division of Johnson & Johnson to treat severe mental conditions.
The Food and Drug Administration approved risperidone only for treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Doctors, however, can prescribe it for other conditions.
The Department of Justice and several state attorneys general are investigating Janssen for its sales and marketing of Risperdal.
VA Awards New Contract for Debunked PTSD Drug (by Bob Brewin, NextGov)
VA Spent $717 Million for Useless Post-Traumatic Stress Drug (by David Wallechinsky, AllGov)
- Top Stories
- Unusual News
- Where is the Money Going?
- U.S. and the World
- Appointments and Resignations
- Latest News
- Battling Obesity in U.S., FDA Approves Sweeping New Rules for Calorie Disclosure
- In Blow to Climate Change Fight, EPA Prepares to End Alternative Fuel Program
- Feds Tell Nation’s Cops to Stop Illegally Seizing Motorists’ Property…But Only if they Want To
- Senate Committee Accused of Failing to Interview Men Tortured by CIA for its Torture Report
- U.S. Bombing in Syria Said to Drive More Anti-Assad Rebels to Join or Support ISIS